Examkin

Soru

Zorluk: Çok zorGynecologic Oncology

A 72-year-old woman with severe chronic obstructive pulmonary disease presents with progressive abdominal distension, early satiety, and dyspnea. CT imaging of the chest, abdomen, and pelvis demonstrates an 8-cm complex right adnexal mass, extensive omental caking, massive ascites, and a large right-sided pleural effusion. A multidisciplinary tumor board determines she is an unacceptably high-risk candidate for upfront primary cytoreductive surgery due to her severe pulmonary comorbidities and the massive extent of her disease. Arrange the following steps in the standard evidence-based sequence for the evaluation and management of this patient.

  1. 1Obtain histologic or cytologic confirmation of malignancy via image-guided biopsy or thoracentesis.
  2. 2Administer initial cycles of platinum-based neoadjuvant chemotherapy.
  3. 3Perform interval cytoreductive surgery to achieve maximal removal of macroscopic disease.
  4. 4Complete the remaining planned cycles of postoperative adjuvant platinum-based chemotherapy.
  5. 5Institute targeted maintenance therapy guided by somatic and germline molecular profiling.

Cevap

The correct sequence is: 1) Obtain histologic/cytologic confirmation, 2) Administer neoadjuvant chemotherapy, 3) Perform interval cytoreductive surgery, 4) Complete adjuvant chemotherapy, 5) Institute targeted maintenance therapy.
The standard of care for advanced epithelial ovarian cancer typically involves primary surgical cytoreduction. However, in patients who are poor surgical candidates (e.g., severe COPD) or have massive unresectable stage IV disease (e.g., large pleural effusion, extensive upper abdominal disease), the standard pathway shifts to neoadjuvant chemotherapy (NACT). Before any chemotherapy can begin, a definitive tissue or cytologic diagnosis must be secured, typically via image-guided core biopsy or thoracentesis. After 3-4 cycles of NACT, the tumor burden is reassessed. If there is a favorable response and the patient's surgical risk has improved, interval cytoreductive surgery is performed. Postoperatively, the patient completes the remaining cycles of systemic adjuvant chemotherapy. Finally, based on molecular profiling (such as BRCA1/2 and HRD status), targeted maintenance therapy is instituted to maximize progression-free survival.

Adım Adım Çözüm

1
Identify the clinical scenario and the contraindication to standard primary surgery.
The patient has stage IV suspected epithelial ovarian cancer (pleural effusion) and is a poor surgical candidate due to severe COPD and massive disease burden.
Standard management for ovarian cancer is primary surgical cytoreduction, but neoadjuvant chemotherapy (NACT) is indicated for patients who cannot tolerate prolonged surgery or have unresectable disease.
2
Determine the prerequisite for initiating chemotherapy.
Histologic or cytologic confirmation (via core biopsy or thoracentesis) must be obtained.
Systemic cytotoxic chemotherapy cannot be initiated based solely on imaging and tumor markers; tissue diagnosis is strictly required.
3
Sequence the phases of the neoadjuvant protocol.
Neoadjuvant chemotherapy is followed by interval cytoreductive surgery, which is then followed by adjuvant chemotherapy.
The goal of NACT is to shrink the tumor to make complete surgical resection (interval debulking) feasible, after which the remaining systemic chemotherapy cycles are administered to eradicate micrometastatic disease.
4
Identify the final step in modern advanced ovarian cancer management.
Initiation of maintenance therapy.
Targeted agents like PARP inhibitors (for BRCA-mutated or HRD-positive tumors) or bevacizumab are used as maintenance therapy after completion of primary treatment to delay recurrence.

Anahtar Kavram

Management pathway for advanced epithelial ovarian cancer in poor surgical candidates (Neoadjuvant Chemotherapy pathway).
Bu soruyu puanla

Konular

Gynecologic Oncology

Bu konudan daha fazla soru